Pluri Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pluri Inc. on June 22, 2026, covering events occurring between June 14, 2026, and June 19, 2026. The Company, incorporated in Nevada and headquartered in Haifa, Israel, reported on the entry into a material definitive agreement and changes in its Board of Directors following its 2026 Annual Meeting of Shareholders held on June 15, 2026.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial metric disclosed is the receipt of an advance payment of $1,250,000 under an Advance Subscription Agreement with Chutzpah Holdings LP, beneficially owned by Chairman Alexandre Weinstein. These funds were received on June 16, 2026, and are designated for working capital and general corporate purposes.
Material Changes
- Capital Raise: Entered into an Advance Subscription Agreement for $1,250,000, contingent on a future financing (the "Offering") consummated by August 14, 2026. If the Offering does not occur, the funds will be applied to a separate securities purchase on terms approved by the Board.
- Board Composition: Mr. Eitan Ajchenbaum was not re-elected as a director at the Annual Meeting, resulting in his departure from the Board and his roles as Chairman of the Audit Committee and sole member of the Investment Committee.
- New Director Appointment: Mr. Doron Shorrer, a Company founder and experienced financial professional, was elected to the Board on June 19, 2026. He was appointed Chairman of the Audit Committee (designated as an audit committee financial expert) and sole member of the Investment Committee.
Guidance, Outlook, and Risks
The Company provided no specific financial guidance or revenue outlook in this filing. Management commentary is limited to the intended use of the advance payment for working capital. The filing includes a Safe Harbor Statement highlighting significant risks, including:
- Uncertainty regarding the negotiation and approval of the future Offering.
- Potential delays or obstacles in clinical trials and regulatory approvals.
- Validation of technology and acceptance by the scientific community.
- Competition, pricing pressure, and potential loss of market share.
- Challenges in retaining key employees and unforeseen scientific difficulties.
Investor Verification Checklist
- Verify the final terms and pricing of the future Offering expected by August 14, 2026.
- Confirm the status of the $1,250,000 advance payment and its application toward the Offering or alternative securities purchase.
- Review the Company's cash runway and liquidity position given the reliance on the upcoming Offering for working capital.
- Assess the impact of the Board changes, specifically the transition of Audit Committee leadership from Mr. Ajchenbaum to Mr. Shorrer.
- Monitor updates on clinical trial progress and regulatory filings, as these are cited as material risks to future performance.